

Special Issue

Recent Advances in Skin Cancers

Message from the Guest Editor

While most cutaneous squamous cell carcinomas (cSCCs) are low-risk tumors and treated definitively with surgery, a subset of cSCC is associated with metastasis and death. In recent years, the introduction of the Brigham and Women's Hospital tumor staging system and the updated American Joint Committee on Cancer guidelines have been instrumental in predicting the risk of poor outcomes from cSCC. Gene expression profile testing of cSCC can provide additional prognostic information to guide the implementation of surveillance strategies and adjuvant therapies. The use of immunotherapy, specifically the PD1 inhibitor cemiplimab, has been a game changer in the treatment of locally advanced or metastatic cSCC. In this Special Issue, we will highlight major advances in the staging, prognostication, and treatment of cSCC.

Guest Editor

Dr. Syril Keena T. Que

Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA

Deadline for manuscript submissions

30 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/168321

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)